Mode
Text Size
Log in / Sign up
N/A N=161 Treatment

Clinical Study of the TriVascular Ovation™ Abdominal Stent Graft System

Aortic Aneurysm, Abdominal

Enrolled (actual)
161
Serious AEs
80.1%
Results posted
Dec 2021
Primary outcome: Primary: The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure. — 4 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Ovation™ Abdominal Stent Graft System (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
TriVascular, Inc.
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure.
4
PRIMARY
The Primary Effectiveness Endpoint is Percentage of Subjects That Achieve Treatment Success.
137

Summary

The primary objectives of this study are to determine whether the Ovation Abdominal Stent Graft System is a safe and effective method of treating abdominal aortic aneurysms (AAA's) in those patients considered to be suitable candidates for open surgical repair.

Eligibility Criteria

Inclusion/Exclusion Criteria:

Inclusion Criteria

All patients must meet all of the following inclusion criteria to be eligible for enrollment into this study:

  • Patient is > 18 years of age
  • Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)
  • Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form
  • Patient is considered by the treating physician to be a candidate for elective open surgical repair of the abdominal aortic aneurysm (AAA) (i.e., category I, II, or III per American Society of Anesthesiology (ASA) classification. ASA category IV patients may be enrolled provided their life expectancy is greater than 1 year.
  • Patient has an infrarenal abdominal aortic aneurysm that meets at least one of the following:
  • Abdominal aortic aneurysm ≥5.0 cm in diameter
  • Aneurysm has increased in size by 0.5 cm in last 6 months.
  • Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an adjacent non-aneurysmal aortic segment
  • Patient has patent iliac or femoral arteries that allow endovascular access with the TriVascular Ovation Abdominal Stent Graft System.
  • Patient has a suitable non-aneurysmal proximal aortic neck length of ≥ 7 mm inferior to the most distal renal artery ostium.
  • Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥10 mm. The resultant repair should preserve patency in at least one hypogastric artery.
  • Patient has a suitable non-aneurysmal proximal aortic neck luminal diameter between 16 and 30 mm.
  • Patient has suitable non-aneurysmal distal iliac luminal diameters between 8 and 20 mm.
  • Patient meets the following anatomic criteria: the distance from the most distal renal artery to most superior internal iliac artery measurement is at least 13 cm.
  • Patient has juxtarenal aortic neck angulation ≤ 60º if proximal neck is ≥10 mm and ≤ 45º if proximal neck is 2.0 mg/dl
  • Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.
  • Patient has a known allergy or intolerance to polytetrafluoroethylene (PTFE), PEG-based polymers, fluorinated ethylene propylene (FEP) or nitinol.
  • Patient has a body habitus that would inhibit X-ray visualization of the aorta
  • Patient has a limited life expectancy of less than 1 year
  • Patient is currently participating in another investigational device or drug clinical trial
  • Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pre-treatment, required treatment, and post-treatment procedures and evaluations.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01092117). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search